All In Biotech

Drug Trial Radar · NCT07299747

Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors

A Phase I/IIa Clinical Study Evaluating the Bispecific Antibody-Drug Conjugate VBC103 Targeting Nectin-4 and TROP2 in Subjects With Advanced Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

255

Planned (sponsor's estimate)

Start

Dec 4, 2025

Primary completion

Dec 1, 2027

Study completion Dec 1, 2028

Sponsor

Lead sponsor
VelaVigo Bio IncIndustry
Sponsor type
Industry
First posted
Dec 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, open-label, multi-dose, first-in-human (FIH) Phase I/IIa study to determine the safety and tolerability of VBC103, as well as the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D), PK and further evaluate its efficacy.

Conditions

  • Participants With Advanced Solid Tumor Malignancies

Interventions

  • VBC103Drug

    VBC103

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLT) as defined in the protocolTime frame: (DLT)From time of first dose of VBC103 to end of DLT period (approximately 21 days)
  2. Incidence of Serious Adverse EventsTime frame: From time of Informed Consent to 30 days post last dose of VBC103

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.